Truist Securities Raises Chemours Target Price to $21

Summary

Truist Securities has raised its price target for Chemours Co to $21 from $18, indicating a 22% upside from the last close. The brokerage cites signs of pricing discipline and production curtailments in the titanium dioxide industry, along with anti-dumping duties on Chinese exports, as factors for potential earnings growth starting in 2026. Currently, 5 out of 10 brokerages rate the stock as ‘buy’, 4 as ‘hold’, and 1 as ‘sell’, with a median price target of $15.Reuters

Impact Analysis

So basically, Truist Securities is betting on a turnaround in the titanium dioxide market, which is a core business for Chemours. The timing of this price target hike is interesting, as it aligns with industry signals of improved pricing discipline and production cuts, which could stabilize or even boost margins. The mention of anti-dumping duties on Chinese exports adds another layer of potential competitive advantage for Chemours. However, the real kicker here is the expectation of meaningful earnings growth starting in 2026, suggesting that Truist sees a longer-term play rather than an immediate catalyst. The market might be underestimating this, given the median price target is still $15. If Truist’s thesis plays out, there’s a decent upside, but the risk is whether these industry dynamics actually materialize as expected. Watching how other brokerages adjust their targets could provide further clues on market sentiment.Reuters